β-Blockers Ameliorate A Pathology and Prevent Alzheimer's Disease Progression in a Mouse Model

• 作 者: XiaohuiZhao;GangPei;
• 机 构: Institute of Biochemistry and Cell Biology,Shanghai Institutes for Biological Sciences,Chinese Acade
• 出 处: 第六届海峡两岸生物医学和生物工程学术会议
• 发表日期: 2007年期

　　Amyloid-β (Aβ) is a major pathological determinant of Alzheimers disease (AD).We have shown that β2-adrenergic receptor (β2AR) regulates A production and amyloid plaque formation in vivo (Nat.Med.12,1390-1396 (2006)),which suggests that abnormal activation of β2AR might contribute to A accumulation in AD pathogenesis.Recent ePidemiological evidence suggests that the clinical application of βAR antagonists (β-blockers) is associated with a reduced risk for the development of AD.However,there is no study to directly test the efficacy of β-blockers in AD treatment.